linjc16/ctgov huggingface dataset:
Serum Procalcitonin Level May Predict Acute Kidney Injury in ICU Patients With Sepsis

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to examine if procalcitonin (PCT) can be used for early prediction of AKI septic patients in ICU.

Detailed Description
-----------------
67 patients with sepsis were enrolled in this study. On admission, PCT was measured together with serum creatinine, urea, and other inflammatory markers. Quick Sepsis-related Organ Failure Assessment was calculated at the emergency department. Patients were classified into those with Acute kidney injury (AKI) and non-AKI groups.

Official Title
-----------------
Serum Procalcitonin Level May Predict Acute Kidney Injury in ICU Patients With Sepsis

Conditions
-----------------
Acute Kidney Injury

Intervention / Treatment
-----------------
* Diagnostic Test: measure Serum procalcitonin level


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICU patients with sepsis Exclusion Criteria: Patient known to have End-stage kidney disease Patients on Renal replacement therapy patients without procalcitonin level within 24 hours from admission.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| AKI GROUP<br>measure Procalcitonin among Patient developed Acute kidney injury during ICU stay | Diagnostic Test: measure Serum procalcitonin level<br>* measuring procalcitonin level<br>|
| Non-AKI group<br>measure Procalcitonin among Patient did not develop Acute kidney injury during ICU stay | Diagnostic Test: measure Serum procalcitonin level<br>* measuring procalcitonin level<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| development of AKI | elevated kidney functions creatinine or oliguria | 28 Days |
Aspiration of Subglottic Secretions Using Hi-Lo Evac Endotracheal Tube: Tube Size and Incidence of Suction Lumen Dysfunction

Study Overview
=================
Brief Summary
-----------------
To evaluate the correlation between endotracheal tube size and incidence of dysfunction of suction lumen of Hi-Lo Evac endotracheal tube in critically ill patients who required mechanical ventilation for more than 48 hours.

Detailed Description
-----------------
In mechanically ventilated patients, aspiration of subglottic secretions is a widely used intervention for prevention of ventilator-associated pneumonia. Using Hi-Lo® Evac endotracheal tube (Hi-Lo Evac; Mallinckrodt; Athlone, Ireland), dysfunction of suction lumen and subsequent failure to aspirate the subglottic secretions is not uncommon. The objective of this prospective observational study is to determine the causes and the incidence of suction lumen dysfunction of Evac endotracheal tube.

Official Title
-----------------
Aspiration of Subglottic Secretions in Intubated Critically Ill Patients Using Hi-Lo Evac Endotracheal Tube: Correlation Between Tube Size and Incidence of Suction Lumen Dysfunction

Conditions
-----------------
Aspiration of Subglottic Secretions

Intervention / Treatment
-----------------
* Device: Hi-Lo Evac Endotracheal Tube


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critically ill patients with orotracheal intubation and anticipated duration of intubation more than 48 hours

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Hi-Lo Evac Endotracheal Tube|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ventilator associated pneumonia, prevention, endotracheal intubation, mechanical ventilation
Multicell Air Cushions: Sitting Posture and Limits of Stability

Study Overview
=================
Brief Summary
-----------------
The study's aim is to assess the sitting and dynamic postural control of stability of wheelchair users who have compromised postural control and risk of ulcers while using individually adjusted multi-cell air cushions with and without individual cell-locking function and variable depths.

Official Title
-----------------
Wheelchair Seating: An Assessment of Multicell Air Cushions on Sitting Posture and Limits of Stability

Conditions
-----------------
Wheelchairs, Self-Help Devices, Posture, Sitting Position, Limits of Stability, Balance

Intervention / Treatment
-----------------
* Device: Wheelchair air cushion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: individuals who use a wheelchair have used a wheelchair for no less than 2 years score from 3-6 on the Functional Independence Measure not currently inpatients or those currently accessing acute care for concomitant health-related issues

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: The convenience sample of 15 individuals will each complete the test protocol under the 3 seating conditions in random order.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cushion<br>Three seating conditons (Quadtro Select 10cm, Starlock 10cm, and Starlock 13cm) | Device: Wheelchair air cushion<br>* Reaching tasks during each of the seating conditions decribed in the Arms section.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reach distance | the linear distance from the start position to the furthest reach point during the trial | Day 1 | 
| Accuracy | the ratio of the minimum distance (straight line) from the start position to the total distance traveled until the furthest reach point | Day 1 | 
| Time | length of time from the start position to furthest reached point | Day 1 | 
| total path length of Center of Pressure |  | Day 1 | 
| mean velocity of Center of Pressure |  | Day 1 | 
| pressure-distribution between the seating surface and the two foot Force-sensing arrays |  | Day 1 |
Bioequivalency Study of Perindopril Erbumine 8 mg Tablet Under Fed Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Perindopril Erbumine 8 mg tablet under fed conditions

Official Title
-----------------
A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalency Study of Perindopril Erbumine Tablets 8 mg Under Fed Conditions

Conditions
-----------------
Essential Hypertension

Intervention / Treatment
-----------------
* Drug: perindopril erbumine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Perindopril or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: perindopril erbumine|8 mg tablet|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax |  | 20 Days |
A Study on the Use of a Brace Following Low Back Surgery

Study Overview
=================
Brief Summary
-----------------
This study evaluated the hypothesis that bracing following lumbar spinal fusion surgery improves functional outcome following surgery

Official Title
-----------------
Lumbar Fusion With and Without Postoperative Bracing: A Randomized Prospective Study

Conditions
-----------------
Lumbar Fusion

Intervention / Treatment
-----------------
* Other: lumbar corset


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-80 Undergoing posterior lumbar fusion surgery for degenerative conditions Exclusion Criteria: Unable to complete questionnaires due to language or cognitive barrier Declined study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>brace | Other: lumbar corset<br> <br> |
| Placebo Comparator: 2<br>no brace | Other: lumbar corset<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| functional outcome scores |  | 2 years following surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lumbar fusion
Piezo-surgical Implant With Laser

Study Overview
=================
Brief Summary
-----------------
Evaluation of the effect of laser with piezo-surgical device in dental implants

Official Title
-----------------
Piezo-surgical Implant Placement With Laser

Conditions
-----------------
Effect of Piezo-surgical Implant With Laser on Pain and Swelling in Patients With Missing Teeth

Intervention / Treatment
-----------------
* Device: Piezo-surgery with low level laser therapy
* Device: Piezo-surgery only


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy subjects having good oral hygiene History of bilateral extractions in the lower molar area not less than 6 months ago. Exclusion Criteria: Patients with debilitating diseases or bad oral hygiene, Patients with parafunctional habits and patients who are taking analgesics or with alcohol abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 49 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: split mouth study
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Low level laser therapy<br> | Device: Piezo-surgery with low level laser therapy<br>* Low level laser therapy<br>|
| Active Comparator: Control<br> | Device: Piezo-surgery only<br>* Piezo-surgery only<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of pain |  | 2 hours after surgery | 
| Assessment of pain using visual analog scale |  | 6 hours after surgery | 
| Assessment of pain using visual analog scale |  | 24 hours after surgery | 
| Assessment of pain using visual analog scale |  | 2 days after surgery | 
| Assessment of pain using visual analog scale |  | 3 days after surgery | 
| Assessment of pain using visual analog scale |  | 4 days after surgery | 
| Assessment of pain using visual analog scale |  | 7 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Swelling using swelling score system |  | 2 hours after surgery | 
| Swelling using swelling score system |  | 6 hours after surgery | 
| Swelling using swelling score system |  | 24 hours after surgery | 
| Swelling using swelling score system |  | 2 days after surgery | 
| Swelling |  | 3 days after surgery | 
| Swelling using swelling score system |  | 4 days after surgery | 
| Swelling using swelling score system |  | 7 days after surgery |
Effects of Menthol in E-cigarettes on Smoking Behaviors

Study Overview
=================
Brief Summary
-----------------
The overall goal of this proposal is to understand the relationship between nicotine metabolism and menthol flavor in e-cigarettes on smoking behavior in smokers.

Official Title
-----------------
Effects of Menthol in E-cigarettes on Smoking Behaviors

Conditions
-----------------
Nicotine Dependence

Intervention / Treatment
-----------------
* Drug: Nicotine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 21 years old, able to read and write, use of cigarettes Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: menthol flavor<br>Participants will receive 5% nicotine in an e-cigarette | Drug: Nicotine<br>* Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use<br>|
| Experimental: tobacco flavor<br>Participants will receive 5% nicotine in an e-cigarette | Drug: Nicotine<br>* Participants will receive two nicotine concentrations via e-cigarettes. Each exposure will be 10 3-sec puffs and ad libitum use<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cigarette craving | Labeled Magnitude Scale ; -100 (no sensation) to 100 (strongest imaginable) | up to 3 weeks | 
| Plasma nicotine levels | blood samples obtained at baseline and 2, 5, 15, 30, 45, 60, 90, 120, and 180 minutes after nicotine exposure | up to 3 weeks | 
| Carbon monoxide | breath carbon monoxide will be assessed | up to 2 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| e-cigarette craving | Labeled Magnitude Scale ; -100 (no sensation) to 100 (strongest imaginable) | up to 3 weeks | 
| irritation/harshness | Labeled Magnitude Scale ; -100 (no sensation) to 100 (strongest imaginable) | up to 3 weeks | 
| liking of e-cigarette | Labeled Hedonic Scale ; -100 (most disliked) to 100 (most liked) | up to 3 weeks | 
| coolness | Labeled Magnitude Scale ; -100 (no sensation) to 100 (strongest imaginable) | up to 3 weeks | 
| nicotine withdrawal | Drug effect questionnaire; 0(not at all) to 100(extremely) mm scale | up to 3 weeks | 
| stimulation | Drug effect questionnaire: 0(not at all) to 100(extremely) mm scale | up to 3 weeks | 
| liking of e-cigarette | Drug effect questionnaire: 0(not at all) to 100(extremely) mm scale | up to 3 weeks | 
| e-cigarette use | time line follow back | up to 2 weeks | 
| cigarette use | timeline follow back | up to 2 weeks |
Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea

Study Overview
=================
Brief Summary
-----------------
It is well-known that atrophic gastritis is a major risk factor for gastric cancer, which leads to variations in the serum levels of gastrin, pepsinogen (PG) I, and PGII. We want to assess the effects of age, sex, and Helicobacter pylori status on pepsinogen (PG) level for atrophic gastritis and whether gastric atrophy based on the PG test would be improved after H. pylori eradication.

Conditions
-----------------
Atrophic Gastritis

Intervention / Treatment
-----------------
* Drug: pepsinogen and gastrin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: over 19 years the patients who have gastrointestinal discomfort or get esophagogastroduodenoscopy (EGD) for health check up the patients who got the procedure, endoscopic submucosal resection (ESD) for early gastric cancer Exclusion Criteria: gastrectomy history advanced gastric cancer (impossible to get the gastrectomy) Helicobacter eradication history the patients who have chronic disease cancer patients except gastric cancer within 6 months who cannot perform this study according to research's decision who have bleeding tendency (ex. taking antiplatelet agent, low platelet count or abnormal coagulation time)

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| gastritis and pepsinogen<br> | Drug: pepsinogen and gastrin<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the change of pepsinogen level before and after H. pylori eradication | to compare the change of the pepsinogen level before and after H. pylori eradication and evaluate the correlation between the pepsinogen level and the atrophic gastritis | baseline and 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
atrophic gastritis, pepsinogen, Helicobacter pylori
Unified Airway Model

Study Overview
=================
Brief Summary
-----------------
Chronic rhinosinusitis (CRS) impacts approximately 5% of Canadians. CRS patients suffer from a combination of symptoms that include facial pain, nasal obstruction, hyposmia and mucopurulence discharge. Asthma may additionally worsen quality of life and many patients suffer from both conditions. The unified airway model illustrates a link between both conditions as tissue from the middle ear to the sinus cavity to the lungs function as one unit. Despite evidence for the unified airway model in the setting of CRS and asthma, there are no studies to our knowledge that have evaluated the microbiome (the resident microbes and their genetic expressions that affect disease) of the upper and lower airways in this patient population. Determining the microbiome of the upper and lower airways in patients suffering from CRS and asthma will further support the unified airway model but more importantly, will help contribute to understanding the pathophysiology of this inflammatory process and may help guide future management.

Official Title
-----------------
Unified Airway Model: Comparison of the Microbiome of the Upper and Lower Airways in Chronic Rhinosinusitis and Asthma Patients

Conditions
-----------------
Chronic Rhinosinusitis (Diagnosis), Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 19 years or older Able to speak and understand English Diagnosed with chronic rhinosinusitis with or without asthma and COPD or with a sinonasal tumor Undergoing sinus surgery in St Paul's Hospital Exclusion Criteria: Oral antibiotics in the past month prior to surgery; Immunocompromised; Prior lung transplants; Known sinonasal or bronchial tumors, current or previous; Smoking; Known bleeding disorders: Deemed unfit by the rhinologists/respirologist for bronchoscopy.

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CRS with Asthma<br> | |
| CRS without Asthma<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathology (histological assessment) | Objective is to characterize the pathology (histological assessment) of 'diseased' and 'non-diseased' tissue in CRS patients undergoing sinus surgery as assessed by their pre-surgery CT scan results and stratify based on comorbid lung disease | 1 day | 
| Gene Expression Patterns | Objective is to compare the upper and lower airway pathology and gene expression patterns with in patients with CRS +/- asthma compare to non-CRS patients | 1 day |